Perampanel
- Generic Name
- Perampanel
- Brand Names
- Fycompa
- Drug Type
- Small Molecule
- Chemical Formula
- C23H15N3O
- CAS Number
- 380917-97-5
- Unique Ingredient Identifier
- H821664NPK
- Background
Perampanel is a noncompetitive AMPA glutamate receptor antagonist. It is marketed under the name Fycompa™ and is indicated as an adjunct in patients over 12 years old for the treatment of partial-onset seizures that may or may not occur with generalized seizures. The FDA label includes an important black-boxed warning of serious or life-threatening behaviora...
- Indication
Perampanel is indicated for the treatment of partial-onset seizures with or without secondarily generalized seizures in epileptic patients four years of age and older. It is also indicated as an adjunct in the treatment of primary generalized tonic-clonic seizures in epileptic patients aged 12 years and older.
- Associated Conditions
- Epilepsy, Primary Generalized Tonic-Clonic Seizures, Partial-Onset Seizures
- Associated Therapies
- -
Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of Perampanel in Healthy Subjects
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01396590
Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of Perampanel in Healthy Subjects
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2012-05-04
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 54
- Registration Number
- NCT01396577
A Efficacy and Safety Study of Adjunctive Perampanel in Primary Generalized Tonic Clonic Seizures
- Conditions
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2017-08-28
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 163
- Registration Number
- NCT01393743
A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects
- First Posted Date
- 2010-11-15
- Last Posted Date
- 2013-05-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 22
- Registration Number
- NCT01240187
- Locations
- 🇬🇧
Quotient Clinical, Edinburgh, United Kingdom
A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in Adolescents
- First Posted Date
- 2010-07-13
- Last Posted Date
- 2019-05-15
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 133
- Registration Number
- NCT01161524
A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)
- First Posted Date
- 2009-05-18
- Last Posted Date
- 2018-08-29
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT00903786
Evaluation of the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
- First Posted Date
- 2008-08-14
- Last Posted Date
- 2016-03-14
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1218
- Registration Number
- NCT00735397
Evaluating Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial Seizures
- First Posted Date
- 2008-06-18
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 712
- Registration Number
- NCT00700310
- Locations
- 🇦🇺
The Queen Elizabeth Hospital, Woodville, South Australia, Australia
🇷🇺Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
🇭🇰Queen Mary Hospital, Hong Kong, Hong Kong
Assessment of Perampanel (E2007) on Synaptic Dopamine in Mild-moderate PD Patients: A Pilot Study With [^123I]-IBZM SPECT
- First Posted Date
- 2007-12-03
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 1
- Registration Number
- NCT00566462
- Locations
- 🇺🇸
inVentiv, The Woodlands, Texas, United States
🇺🇸Kenneth Marek, New Haven, Connecticut, United States
🇺🇸Molecular NeuroImaging, LLC, New Haven, Connecticut, United States
Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations
- First Posted Date
- 2007-07-23
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Eisai Limited
- Target Recruit Count
- 328
- Registration Number
- NCT00505622
- Locations
- 🇫🇷
Centre d'Investigation Clinique, Hospital Purpan, Toulouse, Toulouse Cedex, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.